Browsing by Author "Gurbuz, Ali Fuat"

Now showing 1 - 3 of 3

Determinants of Recurrence in Itp Treatment
(E-century Publishing Corp, 2020) Demircioglu, Sinan; Gurbuz, Ali Fuat
Objective: Immune thrombocytopenia (ITP) is the most common cause of thrombocytopenia. Two-thirds of the cases respond to first-line therapy with corticosteroids. However, there is a 50% relapse rate six months after the treatment. Information predicting recurrence at the time of the diagnosis is limited. This study aimed to investigate the relationship of mean platelet volume (MPV) and the neutrophil/lymphocyte ratio (NLR) at the time of the diagnosis with ITP recurrence. Methods: The study included 171 adult primary ITP patients who received corticosteroids and/or intravenous immunoglobulin (IVIG) as first-line therapy. The relationship between the demographic characteristics of the patients and the laboratory values at the time of the diagnosis with the frequency of recurrence was evaluated. Results: A total of 126 (73.7%) female and 45 (26.3%) male patients with a mean age of 38.54 +/- 17.41 years were included in the study. 89 (52%) patients had a recurrence after first-line therapy. No relationship was found between the frequency of recurrence and age, gender, the presence of comorbid diseases, bleeding status, type of the first-line treatment, CRP, and MPV values. However, there was a statistically significant relationship between NLR increase and the frequency of recurrence (P=0.049). Conclusion: In this study, an association was found between the NLR levels and the rate of recurrence in ITP patients receivingfirst-line treatment. Further studies with larger sample sizes are needed to support this finding.
Evaluation of Transfusion Transmitted Infections and Distribution of Abo and Rh Blood Groups in Donors in Eastern Turkey
(2019) Demir, Cengiz; Dogan, Ali; Demircioğlu, Sinan; Gurbuz, Ali Fuat; Kara, Osman; Merter, Mustafa; Ekinci, Ömer
Aim: Knowledge of blood group distribution and blood serology in a given region is critical for the proper functioning of blood banksand also for delivering the blood products to need owners. We aimed to determine the distribution rates of ABO and Rh blood groupsand the incidence of transfusion-transmitted infections in the healthy donors in our region.Materials and Methods: A total of 108,368 healthy individuals were participated in this study. Incidence of HBsAg, anti-HCV, anti-HIV-1/2 and syphilis along with blood group distribution were evaluated retrospectively.Results: Of the blood donors, 98,901(% 91.24) were male and 9,467 (%8.76) were female. Frequency of O, A, B, and AB blood groupdistribution in the donor population were 31.2%, 44.0%, 16.2%, and 8.6%, respectively. Of the blood donors, 95,039 (87.7%) were Rhpositive and 13,229 (12.3%) were Rh negative. A total of 1,685 donors (1.55%) tested positive for HBsAg, 102 (0.09%) for anti-HCV, 23(0.022%) for anti-HIV-1/2, and 58 (0.05%) tested positive for syphilis.Conclusion: The ABO and Rh blood antigens distribution rates found in our study were similar for male and female and resembledthe overall rates for Turkey. When looking at the annual analysis of the donor group, we observed a significant decrease of HbsAgtest positivity over a seven-year-period (p values for time periods 2008-2009, 2010-2011, 2012-2013, 2014-2015 were 0.016, 0.02,0.001, and 0.003 respectively). We believe that our results will be useful for the creation of a database on blood group distributionand the seroprevalence of infectious agents.
Prognostic Effect of Kelim Score of Prostate-Specific Antigen in Hormone-Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways
(Wiley, 2025) Ilhan, Yusuf; Araz, Murat; Gurbuz, Ali Fuat; Urvay, Semiha; Urun, Muslih; Ercek, Berrak Mermit; Beypinar, Ismail
Background The prognostic value of the PSA ELIMination rate constant K (PRO-KELIM) score was investigated in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel androgen receptor inhibitors. Methods This multicenter retrospective study included 160 patients diagnosed with prostate adenocarcinoma between 2011 and 2024 who received enzalutamide or abiraterone during the mCSPC and had at least three PSA measurements within the first 100 days of treatment. The patients were categorized into favorable (PRO-KELIM >= 1.0) and unfavorable (PRO-KELIM < 1.0) groups. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier survival analysis and Cox regression. Results Median PFS was significantly higher in the favorable group than in the unfavorable group (not reached vs. 40.0 months, p < 0.001). The estimated 2-year PFS rates in the favorable and unfavorable groups were 78% and 52%, respectively. In multivariate analyses, a high PRO-KELIM score (HR 2.99; 95% CI 1.35-6.66, p = 0.007) and good initial response to treatment (p = 0.001) were independent favorable prognostic factors for PFS. The median OS did not differ significantly between the groups (p = 0.27). PRO-KELIM score was not an independent prognostic factor for OS (p = 0.76). Conclusion These findings suggest that the PRO-KELIM score can be a valuable prognostic tool in the mCSPC to assess early treatment response and predict disease progression.